Sunpharma Management Guidance Tracker

Management reiterated full-year R&D guidance, with potential updates if needed. Concert Pharma costs are included.

Management expects R&D expenses to remain at similar levels or increase due to clinical trial ramp-up.

Management aims to grow India formulation business faster than the Indian pharmaceutical market on an annualized basis.

Phase III for MM-II and Phase II for GL0034, initially expected early 2024, are now slated to begin in the second half of 2024.

Partner product Nidlegy is expected to be filed with European authorities during the first half of 2024.

R&D investments will increase to 8-10% of sales for the next year, primarily for specialty pipeline.

Management expects R&D investment to increase in subsequent quarters, with full-year guidance of 8-10% of sales.

R&D spend for FY25 is expected to be in the range of 7-8% of sales, down from earlier guidance of 8-10%, due to delays in clinical studies.

Phase III data for Ilumya in psoriatic arthritis is expected in the second half of calendar year 2025, with launch shortly after approval.

Leqselvi to be launched in the US in the second quarter of FY2026.

Sun Pharma plans to file for psoriatic arthritis indication for ILUMYA before end of calendar year 2025.

Management expects full-year R&D spend to be at the lower end of the guided 6-8% range.

Sun Pharma plans to file Ilumya for psoriatic arthritis indication in the second half of FY26.

Sun Pharma plans to launch generic semaglutide in India on day one of patent expiry for both chronic weight management and type 2 diabetes, under brands NovelTreat and SemaTrinity.

CEO Kirti Ganorkar expressed confidence that India formulation growth will align with IPM growth, recovering from NLEM and sitagliptin impacts.

CFO noted that lenalidomide sales were significant in Q1 but will be episodic going forward, not a steady revenue stream.

Management expects consolidated top-line growth in high single digits for FY2025, driven by all business segments.

Q3 specialty sales benefited from inventory build at a partner; next quarter sales are expected to be lower excluding milestones.

Management expects consolidated top-line growth of mid-to-high single digits for FY2026.

Unloxcyt remains on track for US launch in the second half of FY26, with sales force already in place.

Management confirmed that the partial clinical hold on 12mg has been lifted, and 8mg dosing continues as planned with no delays.

Tax rate expected to be higher than last year's 8.8% due to profit mix across jurisdictions.

Management indicated that R&D spend for the full year is expected to reach the lower end of the 7% of sales guidance.

Launch timing of Leqselvi will be governed by court ruling on Incyte's motion; company opposes and seeks early outcome.

Management stated they would be ready to launch Leqselvi within a couple of weeks post a favorable court ruling on the patent litigation.

Due to delays in clinical trial initiation, R&D expenditure for FY25 is expected to be below the earlier guidance of 7% of sales.

Oral arguments for Leqselvi patent litigation expected in April 2025; if favorable, launch could occur before patent expiry in December 2026.

FY2026 R&D spend expected to be 6%-8% of sales.

Management expects to incur approximately $100 million in direct costs (excluding amortization) for the launches of Leqselvi and UNLOXCYT during FY2026.

CFO guided for an effective tax rate of approximately 25% for the full fiscal year, up from 16-17% last year.

Management indicated they will provide R&D spend guidance for the next fiscal year in the next quarter's call.

The phase 2b study for GL0034 in type 2 diabetes has started and is expected to complete within 12-18 months.

Deuruxolitinib is on track for launch after the July 2024 PDUFA date, with pre-launch costs already being incurred.

UNLOXCYT will be launched in the U.S. in the second half of FY2026, pending label update.

Tax rate expected to rise due to expiry of certain exemptions; should be viewed on an annualized basis.

Approximately $100 million additional spend in FY26 for commercialization of new specialty products.

The company expects to spend around $100M in FY26 to support Leqselvi and Unloxcyt launches, with increases in Q3 and Q4.